DSS Announces Licensing of Impact BioMedical’s Linebacker Portfolio to ProPhase Labs

ROCHESTER, N.Y., July 21, 2022 (Globe NEWSWIRE) — DSS, Inc. (NYSE American: DSS), a multinational firm running corporations inside nine divisions and strategically getting and acquiring assets to enrich the value of its shareholders via calculated IPO spinoffs and a parametric share distribution approach, now declared International BioLife, Inc. (“Global BioLife”), a subsidiary of the Company’s wholly owned subsidiary Effects BioMedical, Inc. (“Impact BioMedical”), executed a license arrangement with ProPhase BioPharma, Inc. (“PBIO”), a subsidiary of ProPhase Labs, Inc. (Nasdaq: PRPH), a rapidly developing and diversified diagnostics, genomics and biotech business, for World BioLife’s Linebacker portfolio (LB-1 and LB-2), two patented little molecule PIM kinase inhibitors with major prospective throughout several therapeutic indications.

Ted Karkus, ProPhase Lab’s Chief Govt Officer, commented in a push launch issued on July 21, 2022, “We feel the Linebacker platform has multi-billion-dollar likely in oncology as properly as substantial possible in other fields. In the near time period, we intend to initiate additional enhancement and research of LB-1 as a opportunity cancer co-treatment.”

“The compounds that ProPhase certified have tremendous potential and signify years of scientific study. I certainly imagine that the Linebacker portfolio represents a probable breakthrough in most cancers study. I am thrilled to carry on to perform on these compounds with ProPhase towards commercialization to finally make improvements to the well being and help you save the life of so a lot of,” commented Daryl Thompson, President of GRDG.

“The execution of this licensing arrangement signifies is a substantial milestone for Impression BioMedical and its sturdy portfolio of progress opportunities,” reported Frank D. Heuszel, CEO of DSS. “This is the second license agreement with ProPhase this year, and we are enthusiastic to deepen our operate with each other as they apply their practically 3 a long time of working experience boosting the health of the public.”

Story carries on

LineBacker is a platform of modest molecule X-bonded polyphenols. X-bonding is a molecular tuning method that modifies a normal compound to induce efficiency, efficacy, bioavailability, and trans-membrane permeability even though maintaining security, toxicity, and tolerability. Organic polyphenols have shown solid potential in managing and stopping a assortment of disorders by inhibiting TNF- and sign certain triggers (e.g. neurology, anti-inflammatory, oncology). Two novel discrete LineBacker molecules have been synthesized and characterized together with in vitro screening.

LineBacker is anticipated to be effective in crossing the blood-brain barrier and would be delivered orally. Substantial pre-medical screening has been completed in neurology, anti-inflammatory, oncology, anti-infective, and viral disease states to exhibit reaction to LineBacker.

Daryl Thompson and GRDG plan to get the job done with ProPhase to go on the enhancement of the Linebacker portfolio, as well as on other important compounds in the future.

About DSS, Inc.

DSS is a multinational business functioning firms inside nine divisions: Item Packaging, Biotechnology, Direct Marketing, Business Lending, Securities and Financial investment Management, Option Trading, Digital Transformation, Secure Living, and Choice Strength. DSS strategically acquires and develops assets to enrich the worth of its shareholders through calculated IPO spinoffs and a parametric share distribution tactic. Considering the fact that 2019, under the steerage of new management, DSS has built the needed foundation for achievable progress through the development of a diversified portfolio of organizations positioned to drive profitability in several substantial development sectors. These businesses offer you progressive, flexible, and serious-earth answers that not only give mutual benefits for enterprises and their buyers, but also make sustainable value and opportunity for transformation.

For additional facts on DSS visit http://www.dssworld.com.

Safe Harbor Disclosure

This push launch contains ahead-looking statements that are designed pursuant to the protected harbor provisions inside the meaning of Section 27A of the Securities Act of 1933, as amended, and Portion 21E of the Securities Exchange Act of 1934, as amended. This sort of ahead-looking statements contain, but are not constrained to, statements relevant to the Company’s meant use of proceeds and other statements that are not historical info. Ahead-wanting statements are based mostly on management’s current anticipations and are topic to risks and uncertainties that may bring about actual outcomes or activities to differ materially from all those projected. These dangers and uncertainties, several of which are further than our handle, contain: challenges relating to our expansion technique our capacity to obtain, execute less than and manage financing and strategic agreements and associations pitfalls relating to the effects of improvement actions our capacity to appeal to, integrate and retain critical personnel our want for sizeable further money patent and mental residence issues competitors as very well as other challenges described in the part entitled “Chance Factors” in the prospectus and in our other filings with the SEC, such as, without having limitation, our reviews on Forms 8-K and 10-Q, all of which can be attained on the SEC web site at www.sec.gov. Visitors are cautioned not to area undue reliance on the forward-looking statements, which talk only as of the date on which they are made and mirror management’s existing estimates, projections, anticipations, and beliefs. We expressly disclaim any obligation or undertaking to launch publicly any updates or revisions to any ahead-seeking statements contained herein to replicate any modify in our expectations or any variations in situations, disorders, or situations on which any such statement is based, apart from as essential by law.

Investor Relations Make contact with:

Dave Gentry
RedChip Providers Inc.
1-800-Purple-CHIP (733-2447)
Or 407-491-4498
[email protected]